TNFRSF17 and plasma cell myeloma: Similar to sBCMA [10, 12], we found low levels of BCMA-EV in healthy donors and a correlation of BCMA-EV with disease status as BCMA-EV levels in heavily pretreated patients were significantly higher than in myeloma patients without prior treatment or in early course of therapy.